Willow Biosciences Completes Brokered Private Placement
On July 18,
2024, Willow Biosciences Inc. (TSX: WLLW; OTCQB: CANSF) (“Willow”), a leading
biotechnology company focused on revolutionizing industrial manufacturing of
pure, consistent and sustainable functional ingredients, completed its brokered
private placement of units of the company at a price of $0.10 per unit.
The offering
was conducted by Independent Trading Group (ITG) Inc., who acted as lead agent
and sole bookrunner on a “best efforts” basis. Willow intends to use the
proceeds of the offering to support its enzyme engineering of existing pipeline
of products, strain engineering of existing pipeline of products, working
capital requirements and general corporate purposes.
Aird & Berlis represented ITG with a team that included Adria Leung Lim, Ryan Cohen and Christian Nianiaris.
-
BioFull bio
Adria enjoys the fast-paced and challenging nature of securities law.
-
BioFull bio
Ryan’s background in business gives him valuable insight and practical experience when representing clients on capital markets and securities ma...
-
BioFull bio
Christian advises clients on a range of capital markets transactions, bringing to bear a strong work ethic and problem-solving skills which make him a...
